Vimarsana
Biggest News Aggregation in the World

Page 3 - Protein Complex News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Protein Complex. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Protein Complex Today - Breaking & Trending Today

D-Bal Max Reviews: Warning! Don't Buy Until You Read This Steroid Report - Vimarsana News

D-Bal Max Reviews: Warning! Don't Buy Until You Read This Steroid Report

D-Bal Max Reviews: Warning! Don’t Buy Until You Read This Steroid Report

ImmunoMet Therapeutics Granted Fast Track Designation by U.S. FDA for IM156 in Idiopathic Pulmonary - Vimarsana News

ImmunoMet Therapeutics Granted Fast Track Designation by U.S. FDA for IM156 in Idiopathic Pulmonary

Search jobs ImmunoMet Therapeutics Granted Fast Track Designation by U.S. FDA for IM156 in Idiopathic Pulmonary Fibrosis HOUSTON--(BUSINESS WIRE)--ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound IM156, an investigational Protein Complex 1 (PC1) inhibitor, being evaluated for idiopathic pulmonary fibrosis (IPF). “Fast Track designation is another im...

ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing - Vimarsana News

ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing

ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing - Phase 1 clinical study recruitment in healthy volunteers is expected to start in Q1 2021 - - - Recently completed Phase 1 trial in oncology patients demonstrated good safety profile - HOUSTON--(BUSINESS WIRE)--ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the I...